ANIX: מכפיל P/S Anixa Biosciences Inc

Anixa Biosciences, Inc. (ANIX) operates in the protected female oncology sector, which remains independent of global macroeconomic fluctuations. The market cap-to-revenue ratio reflects current dynamics, with the current mark equal to 375.70. Such volatility is driven by a virtual R&D model with full research outsourcing, while the brand's strong reputation in vaccine development sustains investment interest.

The efficient operation of Anixa Biosciences, Inc. (ANIX) laboratories developing breast cancer immunotherapy is reflected in the P/S ratio trends on this chart. This multiple correlates the business's market value with revenue, allowing investors to assess the premium paid for every dollar of sales and determine whether the biotech company's capitalization is fair relative to its current operational achievements.